GlassScriptPhysician profile
Randall Humphreys
NPI 1558336503
$8,280.08
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $952 · 2020: $1,084 · 2021: $1,620 · 2022: $1,414 · 2023: $1,537 · 2024: $1,674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,210.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,523.97 | 2019-2024 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $1,356.19 | 2019-2024 | Dupixent |
| Glaxosmithkline, LLC. | $1,158.80 | 2019-2024 | Trelegy Ellipta, Nucala |
| Csl Behring | $750.67 | 2019-2024 | Hizentra |
| Genzyme Corporation | $662.47 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $432.09 | 2019-2022 | |
| Pfizer INC. | $310.26 | 2020-2024 | |
| Octapharma USA, INC. | $295.57 | 2021-2024 | Cutaquig |
| Genentech USA, INC. | $266.04 | 2019-2024 | Xolair |
| Grifols USA, LLC | $248.84 | 2020-2024 | Xembify |
| Novartis Pharmaceuticals Corporation | $237.73 | 2020-2024 | |
| Kaleo, INC. | $207.36 | 2020-2023 | Auvi-Q |
| Amgen INC. | $184.50 | 2021-2024 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $133.43 | 2020-2024 | Takhzyro |
| Pharming Healthcare, INC. | $117.86 | 2022-2024 | Ruconest |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $75.11 | 2021 | |
| Optinose US, INC. | $56.14 | 2020-2021 | |
| Blueprint Medicines Corporation | $42.81 | 2023-2024 | Ayvakit |
| Hikma Pharmaceuticals USA | $34.12 | 2023-2024 | Ryaltris |
| Biocryst Pharmaceuticals, INC. | $32.07 | 2020 | |
| Merck Sharp & Dohme LLC | $28.69 | 2023 | |
| Mylan Specialty L.P. | $25.86 | 2019 | |
| Shire North American Group INC | $21.49 | 2019 | |
| Biocryst US Sales Co., LLC | $21.34 | 2021 | |
| Sanofi-Aventis U.S. LLC | $19.74 | 2020 | |
| Dermavant Sciences, INC. | $18.74 | 2024 | Vtama |
| Leo Pharma INC. | $18.19 | 2023 | Adbry |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Humphreys listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.